To achieve a consensus on optimal blood pressure (BP) targets for older adults remains challenging, necessitating a trade-off between cardiovascular benefits and the risk of impaired organ perfusion. Evidence suggests that age and frailty have a minimal influence on the cardiovascular benefits of intensive BP control in community-dwelling elderly. Nonetheless, an increased incidence of acute kidney injury with intensive BP control has been observed in octogenarians. Therefore, it is recommended to maintain systolic BP below 130 mmHg for hypertensive patients aged 65-80 years. If well-tolerated, a systolic BP target below 120 mmHg can be recommended for patients with chronic kidney disease (CKD). However, no conclusive evidence supports a stringent BP target for patients aged 80 years and older. The selection of antihypertensive medications for elderly patients requires consideration of their cardiovascular condition and potential contraindications. Combination therapy may be necessary to achieve the desired BP target. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are the primary choices for patients with CKD. Newer generation mineralocorticoid receptor antagonists may further reduce the risk of cardiovascular or renal events in this population. In conclusion, managing hypertension in elderly patients requires a personalized approach that balances cardiovascular benefits with potential risks, considering individual health profiles and tolerability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jfma.2024.09.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Using waist circumference as a predictor of hypertension in Manzese, Dar es Salaam: a community-based cross-sectional study, 2023.
BMC Public Health
December 2024
Muhimbili University of Health and Allied Sciences, Dar es salaam, United Republic of Tanzania.
Introduction: It is estimated that 1.3 billion people in the world have hypertension and a large proportion of them are unaware. Waist circumference has emerged as Potential predictor of Cardiovascular Diseases (CVD) risk; however, fewer studies in Tanzania have evaluated its role in screening for CVD risk.
View Article and Find Full Text PDFPrevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial.
Thromb Haemost
December 2024
Department of Brain Sciences, Imperial College London, London, United Kingdom.
Adequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international, phase 3b, multi-center, randomized, open, blinded end-point assessment (PROBE) clinical trial that compared the efficacy and safety of direct oral anticoagulants (DOACs) with no DOAC (either no antithrombotic treatment or any antiplatelet drug).
View Article and Find Full Text PDFIdentifying predictors of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist use in hospital among adults with diabetes.
J Diabetes Complications
December 2024
Sinai Health System, Division of General Internal Medicine, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario. Electronic address:
Aims: To identify factors associated with use of novel diabetes medications among patients hospitalized under general internal medicine.
Methods: We conducted a cohort study of patients with type 2 diabetes mellitus (T2DM) hospitalized in Ontario, Canada between 2015 and 2020. We evaluated the patient- and physician-level factors associated with sodium-glucose cotransporter 2 inhibitor (SGLT2) and glucagon-like peptide 1 receptor agonist (GLP1R) use using a multivariable logistic regression model.
Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System.
Cancer Med
January 2025
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia, USA.
Introduction: Emerging evidence suggests potential cardiovascular toxicities from oral endocrine therapies (ETs); however, results are conflicting. This study comprehensively examined adverse reactions of ETs and investigated cardiovascular and metabolic safety signals within the FDA Adverse Event Reporting System (FAERS).
Methods: Reports in the FAERS through December 2023 were analyzed for documented reactions to tamoxifen, letrozole, anastrozole, and exemestane in female breast cancer patients.
Neurological Nurses' Perspectives on Communication of Stroke Recurrence Risks: A Mixed-Method Study.
J Adv Nurs
December 2024
Nursing and Health School, Zhengzhou University, Zhengzhou, P.R. China.
Aim: To gain a comprehensive understanding of the practices, attitudes, and thoughts of neurological nurses regarding communication about the risk of stroke recurrence.
Design: This is a mixed-method study with a sequential explanatory design.
Methods: An electronic survey was conducted amongst 280 neurological nurses from 30 hospitals to explore their clinical practice and attitudes towards stroke recurrence risk communication (RC).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!